Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 4/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | HTR2B | P41595 | 1/20 | 0.39 |
| ▸ | BCHE | P06276 | 1/20 | 0.38 |
| ▸ | AR | P10275 | 2/20 | 0.36 |
| ▸ | PGR | P06401 | 1/20 | 0.35 |
| ▸ | HTR5A | P47898 | 3/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | F12 | P00748 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12350357 | 1.00 | HTR2C (0.39) | HTR2CHTR2AHTR2BBCHEAR | |
| SCHEMBL29641546 | 1.00 | HTR2C (0.39) | HTR2CHTR2AHTR2BBCHEAR | |
| SCHEMBL12350365 | 1.00 | HTR2C (0.39) | HTR2CHTR2AHTR2BBCHEAR | |
| SCHEMBL5467478 | 0.88 | HTR2C (0.37) | HTR2CHTR2AHTR2BBCHEHTR5A | |
| SCHEMBL25786676 | 0.86 | BCHE (0.39) | HTR2CHTR2AHTR2BBCHEHTR5A | |
| SCHEMBL25604373 | 0.85 | BCHE (0.40) | HTR2CHTR2AHTR2BBCHEHTR5A | |
| SCHEMBL5749290 | 0.78 | HTR2C (0.46) | HTR2CHTR2AHTR2BARHTR5A | |
| SCHEMBL18883053 | 0.78 | HTR2C (0.46) | HTR2CHTR2AHTR2BARHTR5A | |
| SCHEMBL548964 | 0.78 | HTR2C (0.46) | HTR2CHTR2AHTR2BARHTR5A | |
| SCHEMBL13372443 | 0.78 | HTR2C (0.46) | HTR2CHTR2AHTR2BARHTR5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 165 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109529907-B | Nitrogen-doped carbon material supported cobalt catalyst, preparation method thereof and application thereof in catalytic oxidation of N-heterocyclic compound | 中南民族大学 | 2021-10-15 | — | — | CN | claimed |
| CN-111943134-A | Room-temperature dehydrogenation reaction system of photocatalytic organic liquid hydrogen storage material and preparation method and application thereof | 中国科学院理化技术研究所 | 2020-11-17 | — | — | CN | claimed |
| CN-109529907-A | A kind of nitrogen-doped carbon material load cobalt catalyst and preparation method thereof and the application in N- heterocyclic compound catalysis oxidation | 中南民族大学 | 2019-03-29 | — | — | CN | claimed |
| CN-107141252-A | A kind of method that hydrotalcite-like materials are catalyzed nitrogen-containing heterocycle compound oxidative dehydrogenation | 常州大学 | 2017-09-08 | — | — | CN | claimed |
| CN-104649854-A | Cheap and efficient preparation method of aryl halides | UNIV BEIJING | 2015-05-27 | — | — | CN | claimed |
| US-7101869-B2 | 2,4-diaminopyrimidine compounds useful as immunosuppressants | PFIZER INC. (US) | 2006-09-05 | — | — | US | claimed |
| EP-1242403-B1 | 2,4-DIAMINOPYRIMIDINE COMPOUNDS USFUL AS IMMUNOSUPPRESSANTS | PFIZER PROD INC (US) | 2006-01-04 | — | — | EP | claimed |
| US-20030191307-A1 | 2,4-Diaminopyrimidine compounds useful as immunosuppressants | BLUMENKOPF TODD A (US) | 2003-10-09 | — | — | US | claimed |
| CN-122059875-A | Method for synthesizing quinoline compound by catalytic dehydrogenation of tetrahydroquinoline compound | 西安石油大学 | 2026-05-19 | — | — | CN | disclosed |
| EP-3630770-B1 | PYRAZOLO[3,4-B]PYRAZINE DERIVATIVES AS SHP2 PHOSPHATASE INHIBITORS | RELAY THERAPEUTICS INC (US) | 2024-08-28 | — | — | EP | disclosed |
| CN-117143015-A | Synthesis method of tetrahydroquinoline | 温州大学新材料与产业技术研究院 | 2023-12-01 | — | — | CN | disclosed |
| US-20230339902-A1 | TRICYCLIC LIGANDS FOR DEGRADATION OF IKZF2 OR IKZF4 | C4 THERAPEUTICS, INC. (US) | 2023-10-26 | — | — | US | disclosed |
| US-20230339902-A1 | TRICYCLIC LIGANDS FOR DEGRADATION OF IKZF2 OR IKZF4 | C4 THERAPEUTICS, INC. (US) | 2023-10-26 | — | — | US | disclosed |
| US-20230331663-A1 | SMALL MOLECULE NICOTINAMIDE ADENINE DINUCLEOTIDE MODULATORS | THE CLEVELAND CLINIC FOUNDATION | 2023-10-19 | — | — | US | disclosed |
| US-4739063-A | USING CATALYST | PHILLIPS PETROLEUM COMPANY (US) | 1988-04-19 | — | — | US | disclosed |
| US-4739064-A | USING GROUP 8 METAL CATALYSTS AND REACTION MODIFIERS | PHILLIPS PETROLEUM COMPANY (US) | 1988-04-19 | — | — | US | disclosed |
| EP-0198264-A2 | Carbamoyl imidazoles | NIHON TOKUSHU NOYAKU SEIZO K.K. (JP) | 1986-10-22 | — | — | EP | disclosed |
| US-4587341-A | BACTERICIDES | BURROUGHS WELLCOME CO. (US) | 1986-05-06 | — | — | US | disclosed |
| EP-0096214-A1 | Antibacterial pyrimidine compounds | THE WELLCOME FOUNDATION LIMITED (GB) | 1983-12-21 | — | — | EP | disclosed |
| US-4015005-A | TRANQUILIZERS, SLEEP INDUCERS, CNS DEPRESSANTS | SANDOZ, INC. (US) | 1977-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030191307-A1 | 2,4-Diaminopyrimidine compounds useful as immunosuppressants | CCR1, AOC1, NOD1 | HTR2C 2420/4885HTR2A 3872/4885HTR2B 3518/4885 |
| US-20230339902-A1 | TRICYCLIC LIGANDS FOR DEGRADATION OF IKZF2 OR IKZF4 | IKZF1, IKZF3, IKZF2 | HTR2C 3544/4885HTR2A 3868/4885HTR2B 4767/4885 |
| US-20230331663-A1 | SMALL MOLECULE NICOTINAMIDE ADENINE DINUCLEOTIDE MODULATORS | NQO1, NADK, CD38 | HTR2C 4666/4885HTR2A 3716/4885HTR2B 4089/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.